The JAK2V617F mutation is detectable in granulocyte populations at greater than 2 copies per cell among individuals with myeloproliferative disorders Leukemia (2007 Leukemia ( ) 21, 816-817. doi:10.1038 published online 1 February 2007 Unlike previous publications (for a review see McClure et al. 1 ), we recently reported the detection of the JAK2V617F mutation at very low levels in peripheral blood of healthy individuals. 2 Using a sensitive polymerase chain reaction (PCR) method specific to the JAK2V617F mutation, Hammond et al.
3 reported also very low copies of this mutation in granulocyte populations of normal individuals that they assumed to represent nonspecific amplification of the wild-type JAK2 allele. It is difficult to comment accurately on this matter as no technical details are given, but their assumption is probably based on the fact that the 
Figure 2
Twenty nanograms of input DNA (n ¼ 131 samples), as quantified by NanoDrop spectrophotometry, was used in two real-time PCR assays to quantitatively determine JAK2 V617F levels and cell numbers (based on two copies of the HGH gene being amplified per cell), respectively (top left panel). An average of 9887 cells (s.d. ¼ 3291; CV ¼ 33%) per 20 ng of input DNA was measured for all samples, in comparison to the 3333 cells which would be expected to be measured in a perfect DNA extraction and amplification system (assuming one diploid cell carries 6 pg of DNA). Greater cell numbers were measured in samples from possible MPD cases (mean ¼ 10439 cells) compared with controls (mean ¼ 5840 cells). JAK2 V617F levels expressed by either method produced a similar distribution of the data (bottom panels). However, the read-out from the internal locus control assay is more biologically meaningful (i.e., copies/cell) than an absolute number of copies, and the clinical significance of changes in this measurement with treatment may be more easily appreciated. The top three measures of JAK2 V617F levels were from male individuals with grossly hypercellular bone marrow, a diagnosis of polycythemia vera and who were all treated with hydroxy urea.
Letters to the Editor method used is known to potentially generate artefact of the PCR. In our situation, we still believe that normal peripheral blood cells harbouring a JAK2V617F mutation do really exist, as the detection of a mutated allele was obtained with great reproducibility in several genomic DNA and cDNA preparations for each of our healthy positive controls. Furthermore, a mutated sequence was recurrently observed in two of these individuals. Our ability to get a mutated sequence despite a very low level of JAK2V617F-mutated alleles was due to the use of locked nucleic acid (LNA) oligonucleotide that limited the amplification of the wild-type JAK2 sequence and allowed thus to enrich sufficiently the PCR tube with mutated amplicons.
Beside the debate regarding the presence or not of JAK2V617F mutated allele in normal population, Hammond et al. provide interesting results in that they were able to detect gains of the mutated allele in some of their cases of myeloproliferative disorders. These findings are reminiscent of previously described situations where oncogenes (such as mutant EGFR (epidermal growth factor receptor), Met or RET) require either duplication/ amplification of the mutant allele or loss of the wild-type allele to attain optimal tumorigenic potential. [4] [5] [6] If confirmed by other studies, the data proposed by Hammond et al. will bring further insights into the possible molecular mechanisms by which the JAK2V617F mutation contributes to the development of the disease. ''The JAK2 V617F mutation is detectable in granulocyte populations at greater than two copies per cell among individuals with myeloproliferative disorders'', by El Housni et al.
Leukemia ( In our recent letter to Leukemia, 1 we reported that in lieu of a definitive negative control, or the availability of an alternative 'gold standard' methodology to verify the accuracy of our quantitative assay for the JAK2 V617F mutation, we have used healthy controls as a surrogate to assess assay specificity, and also to establish a clinically useful range for supporting a diagnosis of myeloproliferative disorder.
We consider that amplification of small numbers of mutant JAK2 copies in normals could represent either mis-priming, or the presence of 3'-shortened mutation-specific primers (as it is only the very 3'-end base that confers specificity, and 3'-shortened primers will amplify from both wild type and mutant DNA). The primers in our assay were high-performance liquid chromatography (HPLC)-purified and we avoided freeze thawing. However, any reductions in the integrity and quality of the oligonucleotides could potentially contribute to non-specific amplification. Our assumption that low-level amplification of the JAK2 V617F sequence in healthy controls may represent artefact of the polymerase chain reaction (PCR) reaction, is also based on a previous publication, 2 where the authors demonstrated that the specificity of their assay to quantify donor and recipient hemopoietic cells by realtime-PCR of single nucleotide polymorphisms required a cutoff level for the crossing threshold (Ct) of 35 to exclude amplification of the negative allele. Similarly, we did not know whether amplification in healthy controls and in lymphocyte DNA after 36 cycles in our assay represented non-specific amplification of the wild-type JAK2 allele (or granulocyte contamination in the case of DNA from the lymphocyte fraction).
The assessment of non-specific amplification requires the availability of a true negative control. DNA for this purpose may potentially be sourced from clonal populations of cells (that are homogeneously wild type for the JAK2 allele). We adopted an alternative approach to testing assay specificity by serially diluting DNA from a healthy control sample in water and also in DNA from another control sample.
3 Fluorescent detection of a PCR product occurred after 36 cycles for all samples with DNA. However, we observed a poor relationship between the dilution factor and measures of mutational load, consistent with amplification being non-specific.
Our experience has certainly generated an enthusiasm to participate in quality assurance initiatives with groups such as Dr Sidon's et al., 4 where concordance of results for samples exchanged between sites represents the fundamental first step to deriving a meaningful clinical range for normal and disease measurements.
